TriSalus Life Sciences (NASDAQ:TLSI) Rating Increased to Strong-Buy at Northland Capmk

TriSalus Life Sciences (NASDAQ:TLSI) was upgraded by equities researchers at Northland Capmk to a “strong-buy” rating in a report released on Friday, Zacks.com reports.

Several other brokerages have also issued reports on TLSI. Canaccord Genuity Group reissued a “buy” rating and issued a $12.00 target price on shares of TriSalus Life Sciences in a research report on Thursday, June 27th. Oppenheimer initiated coverage on shares of TriSalus Life Sciences in a report on Monday, September 16th. They set an “outperform” rating and a $10.00 target price on the stock. Finally, Northland Securities assumed coverage on shares of TriSalus Life Sciences in a research note on Friday. They issued an “outperform” rating and a $12.50 price target for the company. Five research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $12.50.

TriSalus Life Sciences Price Performance

Shares of NASDAQ:TLSI opened at $4.07 on Friday. TriSalus Life Sciences has a 1 year low of $3.32 and a 1 year high of $10.42. The company has a market cap of $119.29 million, a PE ratio of -1.63 and a beta of 0.47. The stock’s 50-day moving average is $4.70 and its 200 day moving average is $6.39.

TriSalus Life Sciences (NASDAQ:TLSI) last posted its earnings results on Wednesday, August 14th. The company reported ($0.21) EPS for the quarter. The firm had revenue of $7.36 million for the quarter. Analysts expect that TriSalus Life Sciences will post -1.53 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Mary T. Szela bought 7,520 shares of the stock in a transaction on Thursday, September 12th. The shares were acquired at an average price of $5.20 per share, for a total transaction of $39,104.00. Following the purchase, the chief executive officer now owns 377,382 shares of the company’s stock, valued at approximately $1,962,386.40. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 32.80% of the company’s stock.

Institutional Investors Weigh In On TriSalus Life Sciences

A number of institutional investors have recently bought and sold shares of the business. Wolverine Asset Management LLC bought a new stake in TriSalus Life Sciences in the second quarter worth $240,000. Highbridge Capital Management LLC purchased a new stake in shares of TriSalus Life Sciences in the second quarter valued at $1,184,000. Finally, Duquesne Family Office LLC raised its stake in shares of TriSalus Life Sciences by 35.1% in the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock valued at $2,357,000 after acquiring an additional 110,966 shares during the period. Hedge funds and other institutional investors own 2.58% of the company’s stock.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.